Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial

Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial

Abstract This multicenter, single‐arm, phase II clinical trial (NCT04034589) evaluated the efficacy and safety of pyrotinib combined with fulvestrant in patients with HR‐positive/HER2‐positive metastatic breast cancer who had experienced trastuzumab treatment failure. A total of 46 patients were enr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jianli Zhao, Yunfang Yu, Wei Ren, Linxiaoxiao Ding, Yongjian Chen, Peng Yuan, Jian Yue, Yaping Yang, Guorong Zou, Tao Chen, Jie Chai, Li Zhang, Wenjing Wu, Yinduo Zeng, Xiujuan Gui, Yangyang Cai, Simin Luo, Zhongyu Yuan, Kang Zhang, Herui Yao, Ying Wang
Format:	Article
Language:	English
Published:	Wiley 2025-01-01
Series:	MedComm
Online Access:	https://doi.org/10.1002/mco2.70031
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis
by: Yitian Lang, et al.
Published: (2025-01-01)

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study
by: Fei Wang, et al.
Published: (2025-01-01)

Development of a risk prediction nomogram model of pyrotinib-induced severe diarrhea
by: Qingqing Chen, et al.
Published: (2025-01-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

Pyrotinib: A promising therapeutic prospect for treating metastatic salivary gland cancer
by: Dhanraj Ganapathy, et al.
Published: (2024-06-01)

Subtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer
by: Taeyeong Kim, et al.
Published: (2025-01-01)

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial
by: Binghe Xu, et al.
Published: (2025-01-01)

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

The woman and her inner dialogue: How Positive Psychotherapy transforms psychosomatic challenges into strength
by: Elena Drazheva, et al.
Published: (2025-01-01)

Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance
by: Juliane Albrecht, et al.
Published: (2025-01-01)

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024-01-01)

Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study
by: Yan Chen, et al.
Published: (2024-12-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
by: Sara M Tolaney, et al.
Published: (2022-10-01)

Third Swiss Annual Meeting on HER2-Positive Breast Cancer: Recent Advances and New Challenges
by: Marcus Vetter, et al.
Published: (2024-09-01)

A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
by: Xinpei Deng, et al.
Published: (2024-09-01)

HER2-Positive Metaplastic Spindle Cell Carcinoma Associated with Synchronous Bilateral Apocrine Carcinoma of the Breast
by: Katsumi Kito, et al.
Published: (2014-01-01)

Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant
by: Scott Thomas, et al.
Published: (2025-01-01)

Quercetin inhibits truncated isoform of dopamine- and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer
by: Han-Sheng Chang, et al.
Published: (2024-09-01)

c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer
by: Jieun Park, et al.
Published: (2024-01-01)

Molecular characterization and potential therapeutic roles of miR125a in HER-2 positive gastric cancer
by: Afraa Mamoori, et al.
Published: (2023-07-01)

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-01-01)

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
by: Asiye Busra Boz Er
Published: (2024-12-01)

ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer
by: Shufen Mo, et al.
Published: (2025-01-01)

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Correction: c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer
by: Jieun Park, et al.
Published: (2025-01-01)

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
by: Abul Azad, et al.
Published: (2025-01-01)

A phase Ia study of a novel anti-HER2 antibody–drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
by: Chenfei Zhou, et al.
Published: (2025-01-01)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01)

Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
by: Luca Mastrantoni, et al.
Published: (2025-02-01)

Airborne Position and Orientation System for Aerial Remote Sensing
by: Jianli Li, et al.
Published: (2017-01-01)

Exploring the heterogeneity of HER2 gene status and expression in non-positive breast cancer patients: insights from immunohistochemistry and fluorescence in situ hybridization
by: Jingmin Zhong, et al.
Published: (2025-01-01)

Positive Filtering with l1-Gain for Discrete-Time Positive Systems
by: Xiaoming Chen
Published: (2016-01-01)

Research on integrated communication and positioning technology based on visible light
by: Wei WANG, et al.
Published: (2023-05-01)

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)

Optimal Position and Velocity Estimation for Multi-USV Positioning Systems with Range Measurements
by: Wei Chen, et al.
Published: (2018-01-01)

Spatial Position Optimization of Components in the Labeling Robot System for Bundled Bars
by: Zhang Fuxiang, et al.
Published: (2022-10-01)

The Synthesis of the Locating Substitution Derivatives of Chitosan by Click Reaction at the 6-Position of Chitin
by: Yu Chen, et al.
Published: (2015-01-01)